The lack of reliable early‐stage diagnostic modalities has resulted in extremely poor prognoses for HCC patients, and therefore, it is trivial to discover more specific and reliable biomarkers for the early detection of HCC to improve prognostic outcomes.28 Interestingly, a previous review highlighted the use of lncRNAs as potential markers for cancer diagnosis and prognosis.29 In the current study, we aimed to investigate the underlying mechanism of lncRNA F11‐AS1 regulating NR1I3 by binding to miR‐211‐5p, thus serving as a tumour suppressor in HBV‐related HCC progression. The gene discussed is NR1I3; the disease is cancer.